spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ANTARA  

 HSMN NewsFeed - 25 Apr 2014
KCI Presents New Clinical and Economic Evidence at SAWC/WHS Spring 2014 Conference
Devices Wound Care
 HSMN NewsFeed - 11 Feb 2009
Oscient Pharmaceuticals Restructures Commercial Organization
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2008
Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
Oscient Pharmaceuticals Names Aaron D. Berg Vice President of Marketing and Mark A. Glickman Vice President of Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2007
July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Mar 2007
Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
Biopharmacetuicals
 HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 29 Dec 2006
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Nov 2006
FDA Accepts as "Complete Response" Oscient Pharmaceuticals' Submission Following FACTIVE Approvable Letter for Five-Day CAP
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2006
Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co-Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
Oscient Pharmaceuticals and Pfizer, S.A. de C.V. Announce Launch of FACTIVE(R) Tablets in Mexico
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2006
Oscient Pharmaceuticals Receives Approvable Letter from FDA for FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2006
Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Sep 2006
Oscient Pharmaceuticals and Auxilium Pharmaceuticals Agree to Conclude TESTIM(R) Co-Promotion Partnership
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2006
Oscient Pharmaceuticals Completes Acquisition of Cardiovascular Therapy ANTARA(R) 130mg (fenofibrate) Capsules
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 Aug 2006
Oscient Pharmaceuticals and Abbott Canada Enter into Commercialization Agreement for FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2006
Oscient Pharmaceuticals Agrees to Acquire Cardiovascular Therapy ANTARA(R) 130 mg (fenofibrate) Capsules From Reliant Pharmaceuticals
Biopharmaceuticals Acquisitions
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.